These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

681 related articles for article (PubMed ID: 34901959)

  • 1. The utility of
    Kitajima K; Kawanaka Y; Komoto H; Minami T; Yokoi T; Kuribayashi K; Kijima T; Nakamura A; Hashimoto M; Kondo N; Hasegawa S; Yamakado K
    Hell J Nucl Med; 2021; 24(3):186-198. PubMed ID: 34901959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor response evaluation in patients with malignant melanoma undergoing immune checkpoint inhibitor therapy and prognosis prediction using
    Kitajima K; Watabe T; Nakajo M; Ishibashi M; Daisaki H; Soeda F; Tanemura A; Kanekura T; Yamazaki N; Ito K
    Jpn J Radiol; 2022 Jan; 40(1):75-85. PubMed ID: 34287739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of RECIST, EORTC criteria and PERCIST for evaluation of early response to chemotherapy in patients with non-small-cell lung cancer.
    Shang J; Ling X; Zhang L; Tang Y; Xiao Z; Cheng Y; Guo B; Gong J; Huang L; Xu H
    Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1945-53. PubMed ID: 27236466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response to Immune Checkpoint Inhibitor Therapy in Patients with Unresectable Recurrent Malignant Pleural Mesothelioma Shown by FDG-PET and CT.
    Kitajima K; Maruyama M; Yokoyama H; Minami T; Yokoi T; Nakamura A; Hashimoto M; Kondo N; Kuribayashi K; Kijima T; Hasegawa S; Yamakado K
    Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33806464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of EORTC criteria and PERCIST for PET/CT response evaluation of patients with metastatic colorectal cancer treated with irinotecan and cetuximab.
    Skougaard K; Nielsen D; Jensen BV; Hendel HW
    J Nucl Med; 2013 Jul; 54(7):1026-31. PubMed ID: 23572497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The utility of
    Guo R; Yan W; Wang F; Su H; Meng X; Xie Q; Zhao W; Yang Z; Li N
    Cancer Imaging; 2024 Sep; 24(1):120. PubMed ID: 39256860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response evaluation after immunotherapy in NSCLC: Early response assessment using FDG PET/CT.
    Park S; Lee Y; Kim TS; Kim SK; Han JY
    Medicine (Baltimore); 2020 Dec; 99(51):e23815. PubMed ID: 33371161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Total metabolic tumor volume on
    Tricarico P; Chardin D; Martin N; Contu S; Hugonnet F; Otto J; Humbert O
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38649279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of FDG-PET/CT and CT for evaluation of tumor response to nivolumab plus ipilimumab combination therapy and prognosis prediction in patients with unresectable malignant pleural mesothelioma.
    Kitajima K; Kuribayashi K; Minami T; Yokoyama H; Nakamura A; Hashimoto M; Kijima T; Hasegawa S; Kaida H; Yamakado K
    Oncotarget; 2024 Jun; 15():408-417. PubMed ID: 38900646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of modified Response Evaluation Criteria in Solid Tumors, European Organization for Research and Treatment of Cancer criteria, and PET Response Criteria in Solid Tumors for evaluation of tumor response to chemotherapy and prognosis prediction in patients with unresectable malignant pleural mesothelioma.
    Kitajima K; Maruyama M; Minami T; Yokoi T; Kuribayashi K; Kijima T; Hashimoto M; Hasegawa S; Yamakado K
    Nucl Med Commun; 2020 Aug; 41(8):790-799. PubMed ID: 32516245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What
    Turgeon GA; Iravani A; Akhurst T; Beaulieu A; Callahan JW; Bressel M; Cole AJ; Everitt SJ; Siva S; Hicks RJ; Ball DL; Mac Manus MP
    J Nucl Med; 2019 Mar; 60(3):328-334. PubMed ID: 30030343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative analysis of different response criteria at early phase after PD-1 blockade in non-small lung cancer.
    Kaira K; Yamaguchi O; Naruse I; Umeda Y; Honda T; Watanabe S; Ichikawa K; Yanagisawa S; Kasahara N; Higuchi T; Hashimoto K; Miura Y; Shiono A; Mouri A; Imai H; Iizuka K; Ishizuka T; Minato K; Suda S; Kagamu H; Mori K; Seki N; Kuji I
    Cancer Imaging; 2023 Mar; 23(1):23. PubMed ID: 36859341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pilot study on EORTC or PERCIST for the prediction of progression-free survival with nivolumab therapy in advanced or metastatic gastric cancers: A STROBE-compliant article.
    Nakajo M; Kitajima K; Toriihara A; Arigami T; Daisaki H; Nakamura A; Ohtsuka T; Miwa H; Yoshiura T
    Medicine (Baltimore); 2021 Apr; 100(15):e25494. PubMed ID: 33847661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2'-deoxy-2'-[18F] fluoro-D-glucose-PET/CT scans to predict survival early during treatment of locally advanced non-small cell lung cancer (NSCLC).
    Fledelius J; Khalil AA; Hjorthaug K; Frøkiaer J
    J Med Imaging Radiat Oncol; 2016 Apr; 60(2):231-8. PubMed ID: 26678718
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Fledelius J; Winther-Larsen A; Khalil AA; Bylov CM; Hjorthaug K; Bertelsen A; Frøkiær J; Meldgaard P
    J Nucl Med; 2017 Dec; 58(12):1931-1937. PubMed ID: 28490472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison Between
    Rossi G; Bauckneht M; Genova C; Rijavec E; Biello F; Mennella S; Dal Bello MG; Cittadini G; Bruzzi P; Piva R; Ceriani V; Sambuceti G; Lopci E; Morbelli S; Grossi F
    J Nucl Med; 2020 Jul; 61(7):990-998. PubMed ID: 31806768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapy response evaluation with FDG-PET/CT in small cell lung cancer: a prognostic and comparison study of the PERCIST and EORTC criteria.
    Ziai D; Wagner T; El Badaoui A; Hitzel A; Woillard JB; Melloni B; Monteil J
    Cancer Imaging; 2013 Mar; 13(1):73-80. PubMed ID: 23466871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Value of
    Vekens K; Everaert H; Neyns B; Ilsen B; Decoster L
    Clin Lung Cancer; 2021 Sep; 22(5):432-440. PubMed ID: 33879398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of response to stereotactic body radiation therapy for nonsmall cell lung cancer: PET response criteria in solid tumors versus response evaluation criteria in solid tumors.
    Han J; Song Q; Guo F; Du R; Fang H; Kang J; Lu Z
    Nucl Med Commun; 2022 Jun; 43(6):717-724. PubMed ID: 35354781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDG PET/CT for prognostic stratification of patients with metastatic breast cancer treated with first line systemic therapy: Comparison of EORTC criteria and PERCIST.
    Depardon E; Kanoun S; Humbert O; Bertaut A; Riedinger JM; Tal I; Vrigneaud JM; Lasserre M; Toubeau M; Berriolo-Riedinger A; Dygai-Cochet I; Fumoleau P; Brunotte F; Cochet A
    PLoS One; 2018; 13(7):e0199529. PubMed ID: 30011328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.